- Home
- PRTG vs PRPO Comparison
PRTG vs PRPO Comparison
Compare PRTG & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- PRPO
- Stock Information
- Founded
- PRTG 1973
- PRPO N/A
- Country
- PRTG British Virgin Islands
- PRPO United States
- Employees
- PRTG N/A
- PRPO N/A
- Industry
- PRTG Oil & Gas Production
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- PRTG Energy
- PRPO Industrials
- Exchange
- PRTG Nasdaq
- PRPO Nasdaq
- Market Cap
- PRTG 17.7M
- PRPO 17.1M
- IPO Year
- PRTG N/A
- PRPO N/A
- Fundamental
- Price
- PRTG $5.91
- PRPO $14.51
- Analyst Decision
- PRTG
- PRPO
- Analyst Count
- PRTG 0
- PRPO 0
- Target Price
- PRTG N/A
- PRPO N/A
- AVG Volume (30 Days)
- PRTG 231.6K
- PRPO 20.0K
- Earning Date
- PRTG 08-26-2025
- PRPO 08-12-2025
- Dividend Yield
- PRTG N/A
- PRPO N/A
- EPS Growth
- PRTG N/A
- PRPO N/A
- EPS
- PRTG N/A
- PRPO N/A
- Revenue
- PRTG N/A
- PRPO $20,029,000.00
- Revenue This Year
- PRTG N/A
- PRPO N/A
- Revenue Next Year
- PRTG N/A
- PRPO N/A
- P/E Ratio
- PRTG N/A
- PRPO N/A
- Revenue Growth
- PRTG N/A
- PRPO 26.67
- 52 Week Low
- PRTG $2.10
- PRPO $3.90
- 52 Week High
- PRTG $23.01
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- PRTG 45.85
- PRPO 63.53
- Support Level
- PRTG $5.60
- PRPO $13.83
- Resistance Level
- PRTG $6.20
- PRPO $15.47
- Average True Range (ATR)
- PRTG 0.42
- PRPO 1.18
- MACD
- PRTG 0.10
- PRPO -0.01
- Stochastic Oscillator
- PRTG 65.45
- PRPO 62.16
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.